NEW YORK (GenomeWeb News) - Compugen today said it has signed a collaboration with Teva Pharmaceuticals to discovery biomarkers that could predict nephrotoxicity.
The agreement also may be expanded to include biomarker development for hepatoxicity and cardiotoxicity, Compugen said.
Under the agreement, Compugen will use its computational tools and nucleic acid testing technologies to analyze biological samples collected by Teva in a preclinical study.